KRAS and non-small cell lung carcinoma: Mutations in Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) are prevalent in NSCLC, occurring in approximately 25 to 40% of patients (≈5–10% in Asian patients) [4–7].